Copyright: ©Author(s) 2026.
World J Hepatol. Mar 27, 2026; 18(3): 115411
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.115411
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.115411
Figure 3 Forest plot of outcomes.
A: Change in alanine aminotransferase; B: Change in aspartate aminotransferase; C: Percentage change in adiponectin; D: High-density lipoprotein cholesterol; E: Low-density lipoprotein cholesterol; F: Triglycerides; G: Homeostatic model assessment index. CI: Confidence interval.
- Citation: Alam U, Rath S, Ansab M, Kashif A, Sethi FA, Siddiqui HT, Afridi ZAK, Burhan M, Ali MA, Moiz A, Bacha Z, Khan A, Ahmed R, Alatise MB, Kamil KA. Efruxifermin in patients with metabolic dysfunction-associated steatohepatitis: A GRADE-assessed systematic review and meta-analysis. World J Hepatol 2026; 18(3): 115411
- URL: https://www.wjgnet.com/1948-5182/full/v18/i3/115411.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i3.115411